Payment overview · 2025
General Payments
$658.16
15 reported records · 8 companies
Healthcare provider profile · identity verified
Michael Josovitz, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1538152459
Verified facts
What the public records show
CMS Open Payments records show Michael Josovitz, MD received $658.16 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.04 | 22.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $146.26 | 22.2% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $126.07 | 19.1% | 6 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $125.00 | 19.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $30.38 | 4.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $30.00 | 4.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.60 | 4.0% | 1 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $23.81 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $634.35 | 14 |
| Education | $23.81 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $150.04 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $146.26 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $126.07 | 6 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $38.00 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $30.38 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.60 | 1 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $23.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
75 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
340 | 49 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 890 | 192 |
| Atorvastatin Calcium | Atorvastatin Calcium | 706 | 169 |
| Metoprolol Succinate | Metoprolol Succinate | 606 | 116 |
| Losartan Potassium | Losartan Potassium | 588 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 527 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 522 | 102 |
| Metformin Hcl | Metformin Hcl | 508 | 90 |
| Omeprazole | Omeprazole | 373 | 89 |
| Eliquis | Apixaban | 340 | 49 |
| Cephalexin | Cephalexin | 317 | 228 |
| Furosemide | Furosemide | 307 | 68 |
| Simvastatin | Simvastatin | 307 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 298 | 65 |
| Meloxicam | Meloxicam | 279 | 65 |
| Metformin Hcl Er | Metformin Hcl | 231 | 49 |
| Lisinopril | Lisinopril | 225 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 214 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 208 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 206 | 48 |
| Levofloxacin | Levofloxacin | 188 | 134 |
| Diclofenac Sodium | Diclofenac Sodium | 163 | 41 |
| Gabapentin | Gabapentin | 158 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 30 |
| Carvedilol | Carvedilol | 145 | 29 |
| Jardiance | Empagliflozin | 142 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 25 |
| Azithromycin | Azithromycin | 111 | 92 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 22 |
| Mirtazapine | Mirtazapine | 106 | 27 |
| Famotidine | Famotidine | 104 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 102 | 29 |
| Synthroid | Levothyroxine Sodium | 102 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 96 | 24 |
| Finasteride | Finasteride | 95 | 20 |
| Repaglinide | Repaglinide | 92 | 13 |
| Sertraline Hcl | Sertraline Hcl | 92 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 55 |
| Mupirocin | Mupirocin | 90 | 37 |
| Januvia | Sitagliptin Phosphate | 88 | 12 |
| Montelukast Sodium | Montelukast Sodium | 88 | 22 |
| Atenolol | Atenolol | 82 | 15 |
| Allopurinol | Allopurinol | 81 | 18 |
| Glimepiride | Glimepiride | 78 | 17 |
| Enalapril Maleate | Enalapril Maleate | 77 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 20 |
| Alprazolam | Alprazolam | 76 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 15 |
| Farxiga | Dapagliflozin Propanediol | 75 | 13 |
| Vascepa | Icosapent Ethyl | 72 | 12 |
| Ramipril | Ramipril | 70 | 11 |
| Valsartan | Valsartan | 67 | 15 |
| Ozempic | Semaglutide | 65 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | suppressed |
| Linzess | Linaclotide | 59 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 58 | 11 |
| Labetalol Hcl | Labetalol Hcl | 58 | 13 |
| Mometasone Furoate | Mometasone Furoate | 57 | 19 |
| Myrbetriq | Mirabegron | 55 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 11 |
| Prednisone | Prednisone | 51 | 38 |
| Spironolactone | Spironolactone | 50 | 13 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Nystatin | Nystatin | 46 | 14 |
| Lorazepam | Lorazepam | 45 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 36 |
| Clobetasol Propionate | Clobetasol Propionate | 43 | 14 |
| Lansoprazole | Lansoprazole | 43 | suppressed |
| Trulicity | Dulaglutide | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Colchicine | Colchicine | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | 11 |
| Diazepam | Diazepam | 37 | 15 |
| Promethazine Hcl | Promethazine Hcl | 37 | 30 |
| Tresiba Flextouch U-200 | Insulin Degludec | 37 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 36 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Creon | Lipase/Protease/Amylase | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Brilinta | Ticagrelor | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Procto-Med Hc | Hydrocortisone | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | suppressed |
| Multaq | Dronedarone Hcl | 24 | suppressed |
| Proctozone-Hc | Hydrocortisone | 24 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | suppressed |
| Mesalamine Er | Mesalamine | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Naproxen | Naproxen | 22 | 20 |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 20 | 15 |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 18 | suppressed |
| Silodosin | Silodosin | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 17 |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Enulose | Lactulose | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Mesalamine | Mesalamine | 15 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Crestor | Rosuvastatin Calcium | 13 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tribenzor | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $658.16 · 15 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAMZYOS, NUZYRA, Ohtuvayre, Ozempic, RAYALDEE, VOQUEZNA, Veozah, XHANCE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error